ZYDUSLIFE

**USFDA Approval, Guidance Update & Order Win** **

:** Received **final USFDA approval** for **Indocyanine Green for Injection** with **180-day Competitive Generic Therapy (CGT) exclusivity**. **Impact:** **Positive;** exclusivity provides a competitive advantage and supports near-term U.S. revenue growth. ** :** Revised the **Sanand plant revenue guidance** to **₹1,500–2,000 crore** from the earlier **₹3,000 crore**, stating the previous figure was a **slip of the tongue** and erroneous. **Impact:** **Negative;** lower guidance may temper growth expectations and weigh on investor sentiment. ** !RMC Switchgears:** Secured a **₹334 crore order**, exceeding the company's current market capitalization of around **₹313 crore**. **Impact:** **Strongly Positive;** the large order significantly strengthens revenue visibility and highlights robust business momentum.